Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 71
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Microbiol Immunol ; 66(11): 519-528, 2022 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-35909326

RESUMEN

Lactate dehydrogenase (LDH) levels in measles virus (MeV) reinfection cases for the diagnosis of measles have not been extensively studied. Thus, we evaluated the significance of serum LDH in the immune response of patients with MeV reinfection in comparison with those of patients with primary infection. Among 70 patients who tested positive for MeV-RNA, 42 with high MeV-specific IgG avidity (HA) were suspected as cases of reinfection and 28 with low MeV-specific IgG (LA) were suspected as cases of primary infection. The viral loads in the HA group were also lower than those in the LA group (P < 0.001). The titers of MeV-specific IgM and IgG in the HA group were significantly lower and higher, respectively, than those in the LA group (P < 0.001). The total LDH and LDH isozyme levels were elevated in the LA group compared with those in the HA group (P < 0.001). Through receiver operating characteristic curve analyses, we determined that the area under the curve of total LDH level was 0.87 (95% CI 0.74-1.00) and that the discriminatory accuracy was high for total LDH and all isozymes. By stepwise binary logistic regression analysis considering MeV-specific IgG avidity, we developed a model using IgG, IgM, and total LDH as explanatory variables, which was optimal for distinguishing the LA and HA groups (adjusted R2 = 0.773, P < 0.001). Thus, the serum LDH level in addition to IgM and IgG may be useful parameters for differentiating MeV reinfection from primary infection.


Asunto(s)
Virus del Sarampión , Sarampión , Humanos , Reinfección , Afinidad de Anticuerpos , L-Lactato Deshidrogenasa , Sarampión/diagnóstico , Inmunoglobulina M , Anticuerpos Antivirales , Inmunoglobulina G
2.
Pediatr Surg Int ; 36(10): 1173-1180, 2020 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-32696122

RESUMEN

PURPOSE: Oncolytic viral therapy for neuroblastoma (NB) cells with Sindbis virus (SINV) is a promising strategy for treating high-risk NB. Here, we evaluated the possibility of using SINV structural proteins as therapeutic agents for NB since UV-inactivated SINV could induce cytopathogenic effects. METHODS: The cytotoxicity of UV-inactivated SINV toward human NB cell lines NB69, NGP, GOTO, NLF, SK-N-SH, SH-SY5Y, CHP134, NB-1, IMR32, and RT-BM-1 were analyzed. Apoptosis was confirmed by TUNEL assays. To determine the components of SINV responsible for the cytotoxicity of UV-inactivated SINV, expression vectors encoding the structural proteins, namely capsid, E2, and E1, were transfected in NB cells. Cytotoxicity was evaluated by MTT assays. RESULTS: UV-inactivated SINV elicited more significant cytotoxicity in NB69, NGP, and RT-BM-1 than in normal human fibroblasts. Results of the transfection experiments showed that all NB cell lines susceptible to UV-inactivated SINV were highly susceptible to the E1 protein, whereas fibroblasts transfected with vectors harboring capsid, E1, or E2 were not. CONCLUSIONS: We demonstrated that the cytotoxicity of the UV-inactivated SINV is due to apoptosis induced by the E1 structural protein of SINV, which can be used selectively as a therapeutic agent for NB.


Asunto(s)
Neuroblastoma/terapia , Viroterapia Oncolítica/métodos , Virus Sindbis , Proteínas Estructurales Virales/uso terapéutico , Apoptosis/efectos de los fármacos , Fibroblastos/patología , Humanos , Neuroblastoma/patología , Células Tumorales Cultivadas
3.
Int J Med Sci ; 16(10): 1366-1370, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31692913

RESUMEN

Hepatitis A virus (HAV) infection is a major cause of acute hepatitis including acute liver failure. Hepatitis B infection (HBV) occurs worldwide, with the highest rates in Asian and African countries, and there are several reports that HAV infection may have a more severe clinical course in patients with chronic HBV infection. We previously demonstrated that Japanese miso extracts have inhibitory effects on HAV replication. In the present study, we examined the replication of HAV and HBV in a hepatocyte superinfection model and the inhibitory effects of Japanese miso extracts on both viruses. According to the results, HAV infection inhibited HBV replication in superinfected hepatocytes, and Japanese rice-koji miso extracts had inhibitory effects on HAV replication. Our findings provide useful information for clinicians in managing HAV infection in patients with chronic HBV infection.


Asunto(s)
Hepatitis A/tratamiento farmacológico , Hepatitis B Crónica/tratamiento farmacológico , Extractos Vegetales/farmacología , Sobreinfección/tratamiento farmacológico , Replicación Viral/efectos de los fármacos , Línea Celular , Hepatitis A/complicaciones , Hepatitis A/virología , Virus de la Hepatitis A/efectos de los fármacos , Virus de la Hepatitis A/patogenicidad , Virus de la Hepatitis B/efectos de los fármacos , Virus de la Hepatitis B/patogenicidad , Hepatitis B Crónica/complicaciones , Hepatitis B Crónica/virología , Hepatocitos/virología , Humanos , Oryza/química , Extractos Vegetales/uso terapéutico , Glycine max/química , Sobreinfección/complicaciones , Sobreinfección/virología
4.
Int J Med Sci ; 15(11): 1153-1159, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30123052

RESUMEN

Hepatitis A virus (HAV) infection is one of the major causes of acute hepatitis and acute liver failure in developing and developed countries. Although effective vaccines for HAV infection are available, outbreaks of HAV infection still cause deaths, even in developed countries. One approach to control HAV infection is prevention through diet, which can inhibit HAV propagation and replication. Glucose-regulated protein 78 (GRP78) is a member of the heat shock protein 70 family of molecular chaperone required for endoplasmic reticulum stress and stress-induced autophagy. We previously showed that the elevation of GRP78 expression inhibits HAV replication. It has been reported that Japanese miso extracts, which was made from rice-koji, enhance GRP78 expression. In the present study, we used human hepatoma Huh7 cells and human hepatocyte PXB cells to examine the efficacy of Japanese miso extracts as antiviral agents against HAV. Japanese miso extracts enhanced GRP78 expression and inhibited HAV replication in human hepatocytes. Together, these results demonstrate that Japanese miso extracts may partly modulate GRP78 expression and additively or synergistically work as antivirals against HAV infection. Japanese miso extracts can be used as effective dietary supplements for severe hepatitis A.


Asunto(s)
Virus de la Hepatitis A/efectos de los fármacos , Oryza , Extractos Vegetales/farmacología , Alimentos de Soja , Replicación Viral , Animales , Chaperón BiP del Retículo Endoplásmico , Glucosa , Proteínas HSP70 de Choque Térmico/metabolismo , Proteínas de Choque Térmico , Hepatitis A , Humanos , Proteínas de la Membrana/metabolismo , Ratones
5.
Biochem Biophys Res Commun ; 483(1): 694-699, 2017 01 29.
Artículo en Inglés | MEDLINE | ID: mdl-27986562

RESUMEN

Although the interaction between host and hepatitis A virus (HAV) factors could lead to severe hepatitis A, the exact mechanism of acute liver failure caused by HAV infection is not yet fully understood. The effects of metabolic diseases such as dyslipidemia or diabetes mellitus on HAV replication are still unknown. Here, we examined the effects of free fatty acids or high-concentration glucose on HAV replication and the effects on mitogen-activated protein kinase signaling pathway-related genes in human hepatocytes. We discovered a novel effect of free fatty acids or high-concentration glucose on HAV replication in association with a reduction in the expression of glucose-regulated protein 78 (GRP78). We also observed that thapsigargin induced GRP78 expression and inhibited HAV replication. These findings may provide a new interpretation of the relationship between metabolic diseases and severity of hepatitis A and suggest a new understanding of the mechanism of severe HAV infection.


Asunto(s)
Ácidos Grasos no Esterificados/farmacología , Glucosa/farmacología , Proteínas de Choque Térmico/metabolismo , Virus de la Hepatitis A/efectos de los fármacos , Hepatitis A/virología , Interacciones Huésped-Patógeno , Replicación Viral/efectos de los fármacos , Línea Celular Tumoral , Regulación hacia Abajo , Chaperón BiP del Retículo Endoplásmico , Proteínas de Choque Térmico/genética , Hepatitis A/complicaciones , Virus de la Hepatitis A/fisiología , Hepatocitos/efectos de los fármacos , Hepatocitos/virología , Humanos , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Enfermedades Metabólicas/complicaciones , Tapsigargina/farmacología
6.
J Med Virol ; 89(5): 931-935, 2017 05.
Artículo en Inglés | MEDLINE | ID: mdl-27736043

RESUMEN

The contributions of splash from vomiting and the dispersion of dried-up virus from a contaminated floor surface to community gastroenteritis outbreaks caused by Norovirus (NoV) were evaluated, using Feline calicivirus (FCV) as an NoV surrogate. There was no difference in the size distribution of FCV-containing particles around 0.75 µm) collected from a virus-sprayed chamber 1 and 12 hr after nebulization. FCV clearly dispersed after hitting a floor surface contaminated with dried virus. These results suggest that NoV can likely form airborne droplet nuclei, and dust may be the main route of infection transmission. J. Med. Virol. 89:931-935, 2017. © 2016 Wiley Periodicals, Inc.


Asunto(s)
Movimientos del Aire , Calicivirus Felino/aislamiento & purificación , Desecación , Polvo , Microbiología Ambiental , Pisos y Cubiertas de Piso , Virión/aislamiento & purificación , Animales , Infecciones por Caliciviridae/transmisión , Transmisión de Enfermedad Infecciosa , Humanos , Modelos Teóricos
7.
Int J Med Sci ; 14(11): 1088-1093, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-29104462

RESUMEN

BACKGROUND: Genetic variation near the interferon lambda 3 (IFNL3) is known to be associated with response to pegylated interferon (pegIFN) and ribavirin combination therapy in patients with chronic hepatitis C virus (HCV) infection which is often accompanied by hepatic steatosis. AIMS: We examined whether this genetic variation is associated with host lipids and treatment response. METHODS: A total of 101 Japanese patients who had underwent liver biopsy before treatment with pegIFN and ribavirin for HCV genotype 1b infection were retrospectively analyzed for association between IFNL3 genotypes (rs8099917) and clinical factors including histopathological features of the liver. The presence of >5% steatosis in the liver specimen was defined as hepatic steatosis. RESULTS: Forty patients (40%) had liver steatosis before therapy. Patients with IFNL3 minor genotype (non-TT) showed lower low-density lipoprotein cholesterol level (p=0.0045), higher γ-glutamyl transpeptidase level (p=0.0003) and higher prevalence of hepatic steatosis (p=0.0002). Advanced fibrosis [odds ratio (OR) 4.63, p=0.03] and IFNL3 major genotype (OR 0.13, p=0.001) were 2 independent factors for determining the presence of hepatic steatosis. Among the factors associated with sustained virological response, IFNL3 genotype was the most significant predictor, as per multivariate analysis. CONCLUSIONS: Our results confirmed that IFNL3 genotype is associated with hepatic steatosis as well as IFN response.


Asunto(s)
Antivirales/uso terapéutico , Hepatitis C Crónica/tratamiento farmacológico , Hepatitis C Crónica/genética , Interferón-alfa/uso terapéutico , Interleucinas/genética , Ribavirina/uso terapéutico , Adulto , Anciano , Hígado Graso/tratamiento farmacológico , Hígado Graso/genética , Femenino , Genotipo , Humanos , Interferones , Masculino , Persona de Mediana Edad , Estudios Retrospectivos
8.
Int J Mol Sci ; 18(1)2017 Jan 17.
Artículo en Inglés | MEDLINE | ID: mdl-28106726

RESUMEN

Determination of hepatitis C virus (HCV) genotypes plays an important role in the direct-acting agent era. Discrepancies between HCV genotyping and serotyping assays are occasionally observed. Eighteen samples with discrepant results between genotyping and serotyping methods were analyzed. HCV serotyping and genotyping were based on the HCV nonstructural 4 (NS4) region and 5'-untranslated region (5'-UTR), respectively. HCV core and NS4 regions were chosen to be sequenced and were compared with the genotyping and serotyping results. Deep sequencing was also performed for the corresponding HCV NS4 regions. Seventeen out of 18 discrepant samples could be sequenced by the Sanger method. Both HCV core and NS4 sequences were concordant with that of genotyping in the 5'-UTR in all 17 samples. In cloning analysis of the HCV NS4 region, there were several amino acid variations, but each sequence was much closer to the peptide with the same genotype. Deep sequencing revealed that minor clones with different subgenotypes existed in two of the 17 samples. Genotyping by genome amplification showed high consistency, while several false reactions were detected by serotyping. The deep sequencing method also provides accurate genotyping results and may be useful for analyzing discrepant cases. HCV genotyping should be correctly determined before antiviral treatment.


Asunto(s)
Regiones no Traducidas 5'/genética , Genoma Viral/genética , Hepacivirus/genética , Proteínas no Estructurales Virales/genética , Anciano , Anciano de 80 o más Años , Secuencia de Aminoácidos , Antivirales/uso terapéutico , Femenino , Genotipo , Técnicas de Genotipaje/métodos , Hepacivirus/clasificación , Hepacivirus/fisiología , Hepatitis C/sangre , Hepatitis C/tratamiento farmacológico , Hepatitis C/virología , Secuenciación de Nucleótidos de Alto Rendimiento/métodos , Humanos , Masculino , Persona de Mediana Edad , Reproducibilidad de los Resultados , Serogrupo , Serotipificación/métodos , Resultado del Tratamiento , Proteínas del Núcleo Viral/genética
9.
Biochem Biophys Res Commun ; 462(4): 426-32, 2015 Jul 10.
Artículo en Inglés | MEDLINE | ID: mdl-25976675

RESUMEN

We examined the impact of Sindbis virus (SINV) infection on cell cycle progression in a cancer cell line, HeLa, and a non-cancerous cell line, Vero. Cell cycle analyses showed that SINV infection is able to alter the cell cycle progression in both HeLa and Vero cells, but differently, especially during the early stage of infection. SINV infection affected the expression of several cell cycle regulators (CDK4, CDK6, cyclin E, p21, cyclin A and cyclin B) in HeLa cells and caused HeLa cells to accumulate in S phase during the early stage of infection. Monitoring SINV replication in HeLa and Vero cells expressing cell cycle indicators revealed that SINV which infected HeLa cells during G1 phase preferred to proliferate during S/G2 phase, and the average time interval for viral replication was significantly shorter in both HeLa and Vero cells infected during G1 phase than in cells infected during S/G2 phase.


Asunto(s)
Ciclo Celular , Virus Sindbis/patogenicidad , Células HeLa , Humanos , Virus Sindbis/fisiología , Replicación Viral
10.
Biochem Biophys Res Commun ; 466(3): 567-71, 2015 Oct 23.
Artículo en Inglés | MEDLINE | ID: mdl-26388050

RESUMEN

Epigenetics plays a role in the regulation of gene expression. Epigenetic changes control gene expression at the transcriptional level. Our previous study suggested that the La protein, which is mainly localized in the nucleus, was associated with hepatitis A virus (HAV) internal ribosomal entry site (IRES)-mediated translation and HAV replication. The aim of this study was to investigate whether epigenetic compounds have effects on HAV IRES-mediated translation and HAV replication. Sirtinol, a sirtuin inhibitor, inhibited HAV IRES-mediated translation in COS7-HAV-IRES cells. Treatment with 10 µM sirtinol resulted in a significant reduction in the intracellular RNA levels of HAV HA11-1299 genotype IIIA in Huh7 cells. Epigenetic treatment with a sirtuin inhibitor may represent a new treatment option for HAV infection. In conclusion, epigenetic control was involved in HAV IRES-dependent translation and HAV replication. Special attention should also be paid to underlying viral diseases in the clinical use of epigenetic treatments for malignancies.


Asunto(s)
Benzamidas/farmacología , Virus de la Hepatitis A/efectos de los fármacos , Sitios Internos de Entrada al Ribosoma/efectos de los fármacos , Naftoles/farmacología , Sirtuinas/antagonistas & inhibidores , Amantadina/farmacología , Animales , Antivirales/farmacología , Células COS , Línea Celular , Chlorocebus aethiops , Epigénesis Genética/efectos de los fármacos , Virus de la Hepatitis A/genética , Virus de la Hepatitis A/fisiología , Inhibidores de Histona Desacetilasas/farmacología , Interacciones Huésped-Patógeno , Humanos , Sitios Internos de Entrada al Ribosoma/genética , Fosfoproteínas/metabolismo , Biosíntesis de Proteínas/efectos de los fármacos , ARN Viral/genética , ARN Viral/metabolismo , Triazoles/farmacología , Replicación Viral/efectos de los fármacos
11.
Biochem Biophys Res Commun ; 464(4): 1192-1195, 2015 Sep 04.
Artículo en Inglés | MEDLINE | ID: mdl-26212443

RESUMEN

Due to the lack of efficient hepatitis B virus (HBV) infection systems, progress in understanding the role of innate immunity in HBV infection has remained challenging. Here we used human hepatocytes from a humanized severe combined immunodeficiency albumin promoter/enhancer driven-urokinase-type plasminogen activator mouse model for HBV infection. HBV DNA levels in culture medium from these human hepatocytes were 4.8-5.7 log IU/mL between day 16 and day 66 post-infection by HBV genotype C inoculum. HBV surface antigen (HBsAg) was also detected by chemiluminescent immunoassay from day 7 to day 66 post-infection. Western blot analysis revealed that major histocompatibility complex class I-related chain A (MICA), which plays a role in the innate immune system, was induced in HBV-infected human hepatocytes 27 days after infection compared with the uninfected control. MICA was reduced at day 62 and undetectable at day 90. Of interest, MICA expression by human hepatocytes increased after HBV infection and decreased before HBsAg loss. Human hepatocytes derived from chimeric mice with hepatocyte-humanized liver could support HBV genome replication. Further studies of the association between HBV replication and MICA induction should be conducted.


Asunto(s)
Virus de la Hepatitis B/fisiología , Hepatitis B/inmunología , Hepatitis B/virología , Hepatocitos/inmunología , Hepatocitos/virología , Antígenos de Histocompatibilidad Clase I/inmunología , Animales , Línea Celular , Células Cultivadas , Quimera/inmunología , Quimera/virología , Virus de la Hepatitis B/aislamiento & purificación , Humanos , Hígado/citología , Hígado/virología , Ratones , Ratones SCID
12.
Biochem Biophys Res Commun ; 458(4): 908-12, 2015 Mar 20.
Artículo en Inglés | MEDLINE | ID: mdl-25704089

RESUMEN

The JAK2 inhibitor AZD1480 has been reported to inhibit La protein expression. We previously demonstrated that the inhibition of La expression could inhibit hepatitis A virus (HAV) internal ribosomal entry-site (IRES)-mediated translation and HAV replication in vitro. In this study, we analyzed the effects of AZD1480 on HAV IRES-mediated translation and replication. HAV IRES-mediated translation in COS7-HAV-IRES cells was inhibited by 0.1-1 µM AZD1480, a dosage that did not affect cell viability. Results showed a significant reduction in intracellular HAV HA11-1299 genotype IIIA RNA levels in Huh7 cells treated with AZD1480. Furthermore, AZD1480 inhibited the expression of phosphorylated-(Tyr-705)-signal transducer and activator of transcription 3 (STAT3) and La in Huh7 cells. Therefore, we propose that AZD1480 can inhibit HAV IRES activity and HAV replication through the inhibition of the La protein.


Asunto(s)
Antivirales/farmacología , Virus de la Hepatitis A/efectos de los fármacos , Hepatitis A/tratamiento farmacológico , Janus Quinasa 2/antagonistas & inhibidores , Pirazoles/farmacología , Pirimidinas/farmacología , Replicación Viral/efectos de los fármacos , Animales , Células COS , Línea Celular , Chlorocebus aethiops , Hepatitis A/metabolismo , Hepatitis A/virología , Virus de la Hepatitis A/genética , Virus de la Hepatitis A/fisiología , Humanos , ARN Viral/genética , Factor de Transcripción STAT3/metabolismo
13.
Pediatr Surg Int ; 31(12): 1151-9, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-26298056

RESUMEN

PURPOSE: With current treatment regimens, high-risk neuroblastoma (NB) remains largely incurable. Oncolytic viral therapy uses replication-competent viruses, like Sindbis virus (SINV), to kill cancers. The SINV AR339 strain is blood borne and relatively non-virulent. We evaluated the feasibility of SINV AR339 for treating human NB. METHODS: The cytotoxicity and viral growth of SINV AR339 were evaluated for five human NB cell lines, SK-N-SH, IMR-32, LAN-5, GOTO, and RT-BM-1. SINV-induced apoptosis was confirmed by TUNEL assays and PARP-1 cleavage. In vivo effects of SINV on neuroblastoma cell xenografts in nude mice were assessed by intratumoral or intravenous SINV inoculation. RESULTS: In five human NB cell lines, SINV infections induced remarkable cytotoxicity. The mRNA expressions of anti-apoptotic genes, Bcl-2 and Bcl-xL, in LAN-5 and RT-BM-1, which were less sensitive to SINV infection, increased in response to SINV infection, while the other NB cell lines sensitive to SINV infection failed to respond. In nude mice, intratumoral and intravenous SINV inoculations caused significant regression of NB xenograft tumors. CONCLUSION: Our results suggested that SINV AR339 was significantly oncolytic against human NB. Thus, SINV showed promise as a novel therapy for treating NB.


Asunto(s)
Neuroblastoma/terapia , Viroterapia Oncolítica/métodos , Virus Sindbis , Animales , Apoptosis , Línea Celular Tumoral , Modelos Animales de Enfermedad , Estudios de Factibilidad , Femenino , Humanos , Ratones , Ratones Desnudos
14.
Int J Mol Sci ; 16(9): 21177-90, 2015 Sep 07.
Artículo en Inglés | MEDLINE | ID: mdl-26370958

RESUMEN

We examined whether hepatitis C virus (HCV) genotype 1b core- and NS5A-region mutations are associated with response to peginterferon α-2b plus ribavirin combination therapy. A total of 103 patients with high HCV genotype 1b viral loads (≥ 100 KIU/mL) were treated with the combination therapy. Pretreatment mutations in the core region and interferon sensitivity determining region (ISDR) in the NS5A region were analyzed. In univariate analysis, arginine and leucine at positions 70 and 91 in the core region, defined as double wild (DW)-type, were associated with early virologic response (p = 0.002), sustained virologic response (SVR) (p = 0.004), and non-response (p = 0.005). Non-threonine at position 110 was associated with SVR (p = 0.004). Multivariate analysis showed the following pretreatment predictors of SVR: hemoglobin level ≥ 14 g/dL (odds ratio (OR) 6.2, p = 0.04); platelet count ≥ 14 × 104/mm³ (OR 5.2, p = 0.04); aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio < 0.9 (OR 6.17, p = 0.009); DW-type (OR 6.8, p = 0.02); non-threonine at position 110 (OR 14.5, p = 0.03); and ≥ 2 mutations in the ISDR (OR 12.3, p = 0.02). Patients with non-DW-type, non-threonine at position 110, and < 2 ISDR mutations showed significantly lower SVR rates than others (11/45 (24.4%) vs. 27/37 (73.0%), respectively; p < 0.001). SVR can be predicted through core and NS5A region mutations and host factors like hemoglobin, platelet count, and AST/ALT ratio in HCV genotype 1b-infected patients treated with peginterferon and ribavirin combination therapy.


Asunto(s)
Genotipo , Hepacivirus/genética , Hepatitis C/tratamiento farmacológico , Hepatitis C/virología , Interferón-alfa/uso terapéutico , Mutación , Polietilenglicoles/uso terapéutico , Ribavirina/uso terapéutico , Proteínas no Estructurales Virales/genética , Secuencia de Aminoácidos , Antivirales , Quimioterapia Combinada , Femenino , Hepatitis C/complicaciones , Humanos , Interferón alfa-2 , Cirrosis Hepática/etiología , Cirrosis Hepática/patología , Masculino , Oportunidad Relativa , Proteínas Recombinantes/uso terapéutico , Resultado del Tratamiento , Carga Viral , Proteínas no Estructurales Virales/química
15.
Int J Med Sci ; 11(1): 60-4, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24396287

RESUMEN

Hepatitis A virus (HAV) is a causative agent of acute viral hepatitis for which an effective vaccine has been developed. Here we describe ultra-deep pyrosequences (UDPSs) of HAV 5'-untranslated region (5'UTR) among cases of the same outbreak, which arose from a single source, associated with a revolving sushi bar. We determined the reference sequence from HAV-derived clone from an attendant by the Sanger method. Sixteen UDPSs from this outbreak and one from another sporadic case were compared with this reference. Nucleotide errors yielded a UDPS error rate of < 1%. This study confirmed that nucleotide substitutions of this region are transition mutations in outbreak cases, that insertion was observed only in non-severe cases, and that these nucleotide substitutions were different from those of the sporadic case. Analysis of UDPSs detected low-prevalence HAV variations in 5'UTR, but no specific mutations associated with severity in these outbreak cases. To our surprise, HAV strains in this outbreak conserved HAV IRES sequence even if we performed analysis of UDPSs. UDPS analysis of HAV 5'UTR gave us no association between the disease severity of hepatitis A and HAV 5'UTR substitutions. It might be more interesting to perform ultra-deep sequencing of full length HAV genome in order to reveal possible unknown genomic determinants associated with disease severity. Further studies will be needed.


Asunto(s)
Regiones no Traducidas 5' , Virus de la Hepatitis A/genética , Hepatitis A/epidemiología , Hepatitis A/virología , Adulto , Brotes de Enfermedades , Femenino , Virus de la Hepatitis A/aislamiento & purificación , Humanos , Japón/epidemiología , Masculino , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa , Ribosomas/genética , Análisis de Secuencia de ARN/métodos
16.
Int J Mol Sci ; 15(11): 21455-67, 2014 Nov 21.
Artículo en Inglés | MEDLINE | ID: mdl-25421241

RESUMEN

We retrospectively reviewed 413 recipients with hematologic malignancies who underwent hematopoietic stem cell transplantation (HSCT) between June 1986 and March 2013. Recipients with antibody to hepatitis B core antigen (anti-HBc) and/or to hepatitis B surface antigen (anti-HBs) were regarded as experiencing previous hepatitis B virus (HBV) infection. Clinical data of these recipients were reviewed from medical records. We defined ≥1 log IU/mL increase in serum HBV DNA from nadir as HBV reactivation in hepatitis B surface antigen (HBsAg)-positive recipients, and also defined ≥1 log IU/mL increase or re-appearance of HBV DNA and/or HBsAg as HBV reactivation in HBsAg-negative recipients. In 5 HBsAg-positive recipients, 2 recipients initially not administered with nucleos(t)ide analogues (NUCs) experienced HBV reactivation, but finally all 5 were successfully controlled with NUCs. HBV reactivation was observed in 11 (2.7%) of 408 HBsAg-negative recipients; 8 of these were treated with NUCs, and fortunately none developed acute liver failure. In 5 (6.0%) of 83 anti-HBc and/or anti-HBs-positive recipients, HBV reactivation occurred. None of 157 (0%) recipients without HBsAg, anti-HBs or anti-HBc experienced HBV reactivation. In HSCT recipients, HBV reactivation is a common event in HBsAg-positive recipients, or in HBsAg-negative recipients with anti-HBc and/or anti-HBs. Further attention should be paid to HSCT recipients with previous exposure to HBV.


Asunto(s)
Células Madre Hematopoyéticas/virología , Virus de la Hepatitis B/fisiología , Hepatitis B/virología , Activación Viral/fisiología , Adulto , Anciano , ADN Viral/genética , Femenino , Trasplante de Células Madre Hematopoyéticas/métodos , Células Madre Hematopoyéticas/inmunología , Hepatitis B/inmunología , Anticuerpos contra la Hepatitis B/inmunología , Antígenos del Núcleo de la Hepatitis B/inmunología , Antígenos de Superficie de la Hepatitis B/inmunología , Virus de la Hepatitis B/genética , Virus de la Hepatitis B/inmunología , Humanos , Japón , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Receptores de Trasplantes , Activación Viral/genética , Activación Viral/inmunología
17.
J Infect Dis ; 206(3): 415-20, 2012 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-22615316

RESUMEN

We previously reported that hepatitis B virus (HBV) e antigen (HBeAg) inhibits production of interleukin 6 by suppressing NF-κB activation. NF-κB is known to be activated through receptor-interacting serine/threonine protein kinase 2 (RIPK2), and we examined the mechanisms of interleukin 6 regulation by HBeAg. HBeAg inhibits RIPK2 expression and interacts with RIPK2, which may represent 2 mechanisms through which HBeAg blocks nucleotide-binding oligomerization domain-containing protein 1 ligand-induced NF-κB activation in HepG2 cells. Our findings identified novel molecular mechanisms whereby HBeAg modulates intracellular signaling pathways by targeting RIPK2, supporting the concept that HBeAg could impair both innate and adaptive immune responses to promote chronic HBV infection.


Asunto(s)
Antígenos e de la Hepatitis B/metabolismo , Interleucina-6/metabolismo , Proteína Serina-Treonina Quinasa 2 de Interacción con Receptor/metabolismo , Animales , Línea Celular , Regulación hacia Abajo , Regulación de la Expresión Génica/fisiología , Antígenos e de la Hepatitis B/química , Virus de la Hepatitis B , Humanos , Interleucina-6/genética , FN-kappa B/genética , FN-kappa B/metabolismo
18.
Anticancer Res ; 43(7): 2923-2932, 2023 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-37351990

RESUMEN

BACKGROUND/AIM: Sindbis virus (SINV) is a naturally occurring oncolytic virus that kills cancer cells and is less harmful to normal cells. In this study, a recombinant SINV, which expressed green and blue fluorescent proteins, was used to precisely analyze SINV infection and replication. MATERIALS AND METHODS: Antiviral responses, including IFN-ß mRNA, protein kinase R (PKR), NF-B, and caspase 3/7, were analyzed in SINV-infected cancerous HeLa cells and normal human fibroblast TIG-1-20 cells. RESULTS: SINV could infect, replicate, and proliferate both in HeLa and TIG-1-20 cells, causing lytic infection only in HeLa cells. SINV grew preferentially in HeLa cells causing remarkable apoptosis. IFN-ß mRNA expression was suppressed in SINV-infected HeLa cells compared to that in TIG-1-20 cells. Further analyses of PKR and NF-B upstream of IFN-ß induction revealed that the compromised response in the PKR-NF-B pathway during early infection coincided with IFN induction suppression in HeLa cells. CONCLUSION: Dysregulation of PKR in HeLa cells is the determinant of SINV oncolysis.


Asunto(s)
FN-kappa B , Virus Sindbis , Humanos , eIF-2 Quinasa/genética , eIF-2 Quinasa/metabolismo , Células HeLa , FN-kappa B/metabolismo , Proteínas Quinasas , ARN Mensajero/metabolismo
19.
Bioorg Med Chem Lett ; 22(24): 7481-5, 2012 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-23122858

RESUMEN

We have rationally designed and synthesized a novel near-infrared (NIR) photoactivating probe, designated by iDOPE, in which an indocyanine green (ICG) fluorophore is covalently conjugated with a phospholipid moiety, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), to incorporate into liposome bilayers. NIR irradiation showed that iDOPE retained the optical and fluorescence properties of ICG and demonstrated photoactivator characteristics: fluorescence emission at around 820 nm in a solvent, singlet oxygen production, and concentration-dependent heat generation. Additionally, iDOPE was incorporated into liposome bilayers and maintained stable liposomally formulated iDOPE (LP-iDOPE) over 1week under physiological conditions. We also observed the tumor-specific biodistribution of LP-iDOPE of in vivo xenografts. These findings suggest that LP-iDOPE might be a promising tool for NIR optical imaging, photodynamic therapy, and photothermal therapy.


Asunto(s)
Colorantes Fluorescentes/química , Colorantes Fluorescentes/síntesis química , Verde de Indocianina/química , Membrana Dobles de Lípidos/farmacocinética , Neoplasias Experimentales/tratamiento farmacológico , Fosfatidiletanolaminas/química , Animales , Colorantes Fluorescentes/farmacocinética , Humanos , Rayos Infrarrojos , Membrana Dobles de Lípidos/química , Liposomas/química , Ratones , Modelos Moleculares , Estructura Molecular
20.
J Infect Dis ; 204(5): 793-801, 2011 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-21844306

RESUMEN

BACKGROUND: Hepatitis C virus (HCV) nonstructural protein 5A (NS5A) has been shown to modulate multiple cellular processes, including apoptosis. The aim of this study was to assess the effects of HCV NS5A on apoptosis induced by Toll-like receptor (TLR) 4 ligand, lipopolysaccharide (LPS). METHODS: Apoptotic responses to TLR4 ligands and the expression of molecules involved in TLR signaling pathways in human hepatocytes were examined with or without expression of HCV NS5A. RESULTS: HCV NS5A protected HepG2 hepatocytes against LPS-induced apoptosis, an effect linked to reduced TLR4 expression. A similar downregulation of TLR4 expression was observed in Huh-7-expressing genotype 1b and 2a. In agreement with these findings, NS5A inhibited the expression of numerous genes encoding for molecules involved in TLR4 signaling, such as CD14, MD-2, myeloid differentiation primary response gene 88, interferon regulatory factor 3, and nuclear factor-κB2. Consistent with a conferred prosurvival advantage, NS5A diminished the poly(adenosine diphosphate-ribose) polymerase cleavage and the activation of caspases 3, 7, 8, and 9 and increased the expression of anti-apoptotic molecules Bcl-2 and c-FLIP. CONCLUSIONS: HCV NS5A downregulates TLR4 signaling and LPS-induced apoptotic pathways in human hepatocytes, suggesting that disruption of TLR4-mediated apoptosis may play a role in the pathogenesis of HCV infection.


Asunto(s)
Regulación de la Expresión Génica , Hepacivirus/genética , Transducción de Señal/genética , Receptor Toll-Like 4/metabolismo , Proteínas no Estructurales Virales/genética , Apoptosis , Proteína Reguladora de Apoptosis Similar a CASP8 y FADD , Caspasas/metabolismo , Regulación hacia Abajo , Células Hep G2 , Hepacivirus/patogenicidad , Humanos , Factor 3 Regulador del Interferón/metabolismo , Ligandos , Receptores de Lipopolisacáridos/metabolismo , Lipopolisacáridos/fisiología , Antígeno 96 de los Linfocitos/metabolismo , Factor 88 de Diferenciación Mieloide/metabolismo , FN-kappa B/metabolismo , Unión Proteica , Proteínas no Estructurales Virales/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA